/Simplified Equity Change Report (Shanghai Anze)

NEWS

Simplified Equity Change Report (Shanghai Anze)

Shanghai Stock Exchange

2025/12/12

Thalys Medical Technology Group Co., Ltd.

Simplified Equity Change Report

Listed company name: Thalys Medical Technology Group Co., Ltd. Stock listing location: Shanghai Stock Exchange

Stock abbreviation: Saili Medical

Stock code: 603716

Information disclosure obligor: Shanghai Anze Private Equity Fund Management Co., Ltd. (on behalf of Anze Taiying No. 6 Private Securities Investment Fund)

Address: Room 14053, Area 1, Building 1, No. 888, Huanhu West 2nd Road, Lingang New Area, China (Shanghai) Pilot Free Trade Zone

Mailing address: Room 14053, Area 1, Building 1, No. 888 Huanhu West 2nd Road, Lingang New Area, China (Shanghai) Pilot Free Trade Zone

Nature of change in shares: decrease in shares

Signing date: December 11, 2025

Statement of Information Disclosure Obligor

This report is prepared in accordance with the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Measures for the Administration of Acquisitions of Listed Companies", "Standard No. 15 on the Content and Format of Information Disclosure by Companies Offering Securities to the Public - Report on Changes in Equity" and relevant laws, regulations and normative documents.
The information disclosure obligor has obtained the necessary authorization and approval to sign this report, and its performance does not violate or conflict with any provision in the information disclosure obligor's company's articles of association or internal rules.
In accordance with the provisions of the "Securities Law of the People's Republic of China" and "Measures for the Administration of Acquisitions of Listed Companies", this report has fully disclosed the changes in shares held by the information disclosure obligor in Thalys Medical Technology Group Co., Ltd. (hereinafter referred to as the "Company" or "Salys Medical"). As of the date of signing of this report, except for the shareholding information disclosed in this report, the information disclosure obligor has not increased or decreased its equity interests in Saili Medical through any other means.
This change in equity is based on the information stated in this report. Except for the information disclosure obligor, no other person has been entrusted or authorized to provide information not listed in this report or to provide any explanation or explanation for this report.
The information disclosure obligor promises that this report does not contain false records, misleading statements or major omissions, and assumes legal responsibility for its authenticity, accuracy and completeness.

1. Basic information of information disclosure obligors

Legal person name: Shanghai Anze Private Equity Fund Management Co., Ltd. (representing Anze Taiying No. 6 Private Equity Investment Fund)

Unified social credit code: 91310115342105291X

Legal representative: Zhan Jingshu

Date of establishment: July 1, 2015

Registered capital: 10 million RMB

Enterprise type: Limited liability company (natural person investment or holding)

Registered address: Room 14053, Area 1, Building 1, No. 888, Huanhu West 2nd Road, Lingang New Area, China (Shanghai) Pilot Free Trade Zone

Business scope: General projects: Private securities investment fund management services (business activities must be completed after completing registration with the Asset Management Association of China). (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)

Major shareholders: Daying Investment Management (Shanghai) Co., Ltd. holds 40% of the shares, Hangzhou Fukui Information Technology Consulting Co., Ltd. holds 39%, and Shanghai Zhengde Hengyun Enterprise Management Consulting Co., Ltd. holds 21%.

2. Information about the main person in charge of the information disclosure obligor

Name Gender Position Nationality Long-term residence Rights of residence in other countries or regions Zhan Jingshu Female Executive Director, General Manager China China None

The information disclosure obligor’s equity interests in other domestic or overseas listed companies reach or exceed 5% of the company’s issued shares.

As of the date of signing this report, the information disclosure obligor does not have equity interests in other domestic or overseas listed companies reaching or exceeding 5% of the company's issued shares.

Section 3 The purpose of this equity change and subsequent plans

1. The purpose of this change in the equity of the information disclosure obligor

The reason for this change in equity is the investment planning arrangement of the information disclosure obligor.

2. The information disclosure obligor’s plan to change the shares held by the listed company in the next 12 months

According to the "Announcement on the Plan to Reduce the Shareholdings of Shareholders Holding More than 5% of the Shares" disclosed by the company on October 1, 2025 (Announcement No.: 2025-087), due to its own investment planning arrangements, Shanghai Anze plans to invest in three months after 15 trading days from the date of disclosure of this announcement (i.e., from October 30, 2025 to January 2026). 29), through centralized bidding and block trading, the company will reduce its holdings by no more than 4,202,784 shares of the company, accounting for 2% of the company's total capital stock (if any changes in equity capital occur during the reduction period, such as bonus shares, conversion of capital reserves to share capital, conversion of convertible bonds, etc., the proportion of planned reductions will remain unchanged, and the number of reductions will be adjusted accordingly based on changes in the company's total equity capital). As of the signing date of this report, the above-mentioned reduction plan has not yet been completed.

Except for the above-mentioned shareholding reduction plan, the information disclosure obligor has no clear plan, agreement or arrangement to increase or decrease its interest in the listed company in the next 12 months. If relevant equity changes occur in the future, the information disclosure obligors will perform their information disclosure obligations in a timely manner in strict accordance with relevant laws and regulations.

Section 4 Equity Change Methods

1. Information disclosure obligors’ holdings of shares in listed companies before this equity change

Before this equity change, the information disclosure obligor held 12,100,399 shares of Saili Medical, accounting for 5.76% of the total share capital of Saili Medical as of August 20, 2025.

2. Changes in equity this time

As of December 11, 2025, the information disclosure obligor has reduced its holdings of 1,591,200 unrestricted tradable shares of Saili Medical through centralized bidding transactions, accounting for 0.76% of the total share capital of Saili Medical.

Before and after this equity change, the shareholding status of the information disclosure obligor is as follows:

Name of shareholder before this equity change After this equity change Nature of shares Number of shares held Shareholding ratio Number of shares held Shareholding ratio

(shares) (%) (shares) (%) Shanghai Anze Private Equity Fund

Management Co., Ltd.-Anze

Unlimited tradable shares 12,100,399 5.76 10,509,199 5.00 Taiying No. 6 Private Securities

investment fund

Total 12,100,399 5.76 10,509,199 5.00 Note: Because the company's convertible corporate bonds are in the conversion period, the company's total share capital is constantly changing according to the conversion situation. The proportion before the change is based on the total share capital of 210,139,246 shares on August 20, 2025, and the post-change proportion is based on the total share capital on December 10, 2025. 210,183,386 shares calculated.

3. Restrictions on the rights of information disclosure obligors holding equity shares in listed companies

As of the date of signing of this report, the shares of listed companies held by information disclosure obligors do not have any rights restrictions such as shares being pledged or frozen.

Section 5 Information Disclosure Obligor’s Purchase and Sale of Listed Company Shares in the Previous Six Months Except for the changes in equity disclosed this time, the Information Disclosure Obligor has not purchased or purchased listed company shares in the six months prior to the date of signing this report.

Section 6 Other Major Matters

As of the signing date of this report, the information disclosure obligor has truthfully disclosed the relevant information of this equity change in accordance with relevant regulations, and there is no other major information that should be disclosed in accordance with laws and relevant regulations but has not been disclosed.

Section 7 Documents for Inspection

1. Documents for reference

Business license of the information disclosure obligor;
Identity documents of the main person in charge of the information disclosure obligor;
This report signed by the information disclosure obligor.

2. Location for purchasing documents for reference

This report and the above-mentioned reference documents have been deposited with the Securities Department of Thalys Medical Technology Group Co., Ltd. for investors to review.

Statement of Information Disclosure Obligor

I and the organization I represent promise that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal responsibility for its authenticity, accuracy and completeness.

Information disclosure obligor: Shanghai Angze Private Equity Fund Management Co., Ltd. (representing Angze Taiying No. 6 Private Securities Investment Fund) Legal representative: Zhan Jingshu

December 11, 2025 Schedule

Simplified Equity Change Report

Basic situation

Thalys Medical Technology

Name of listed company Group Co., Ltd. Location of listed company Wuhan City, Hubei Province

Division

Stock abbreviation: Saili Medical Stock Code: 603716

Shanghai Anze Private Equity China (Shanghai) Free Financial Management Co., Ltd. Lingang New Trade Pilot Zone

Information disclosure obligor

Name of information disclosure obligor (representing Angze Taiying Sixth District, Huanhu West 2nd Road

Place of registration

Room 14053, Building 1, District 1, No. 888 Private Securities Investment Fund)

Increase□ Decrease√

Number of shares with interests Is there anyone acting in concert? Yes □ None √ remains unchanged, but the shareholders have issued

change

changes □

Is the person with the information disclosure obligation? The person with the information disclosure obligation?

Is the largest stock in a listed company? Yes □ No √ Is it a listed company? Yes □ No √Dong Actual controller

Centralized trading through stock exchanges √ Agreement transfer 

Administrative transfer or change of state-owned shares  Transfer by indirect means □ Equity change method (can be more than

Obtain new shares issued by a listed company □ Execute court ruling □ Select)

Inherit □ Gift □

Others 

Information disclosure obligor disclosure

Stock type: Number of shares owned before RMB ordinary shares.

Number of shares held: 12,100,399 shares and % of issued shares of listed companies

Shareholding ratio: 5.76%

Bank share ratio

After this change in equity, the number of stock types: RMB ordinary dividend disclosure obligor's ownership changed: a decrease of 1,591,200. The number of shares and change ratio: a decrease of 0.76%. The number of shares held after the change: 10,509,199 shares

Shareholding ratio after change: 5.00%

Is the person with the information disclosure obligation

Plan to continue to increase holdings in the next 12 months Yes □ No √

The information disclosure obligor is here

Was in Level 2 in the previous 6 months?

Yes  No √The listed company is traded in the market

stocks

(This page has no text, but is the signature page of the "Simplified Equity Change Report of Thalys Medical Technology Group Co., Ltd.")

Information disclosure obligor: Shanghai Angze Private Equity Fund Management Co., Ltd. (representing Angze Taiying No. 6 Private Securities Investment Fund) Legal representative: Zhan Jingshu

December 11, 2025